|Security||BSE:524804 / AUROBINDO PHARMA LTD.|
Institutional Stock Ownership and Shareholders
AUROBINDO PHARMA LTD. (BSE:524804) has 0 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
AUROBINDO PHARMA LTD. (BSE:524804) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Related News Stories
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for canakinumab as a potential treatment for cardiovascular risk reduction.
The equity market opened on a cautious note but managed to close in the positive after buying in last hour of trade on October 15. It was a volatile session of trade for Nifty but it managed to close at 10,512 up by 0.38 percent. (1-0)
Merger and acquisition (M&A) deal values recorded a 5.3-times increase year-on-year (y-o-y) in the third quarter of calendar year 2018 (Q32018) driven by outbound activity, according to a dealtracker report by Grant Thornton. The report stated that M&A deal values stood at $11.506 billion in Q32018 compared with $2.147 billion in the same period last year.
(Reuters) - European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.
Corporate India announced merger and acquisitions (M&As) worth $11.5 billion in the third quarter of this year, following which the January-September deal tally stood at $76.03 billion, says a report.